… cases involve other mutation sites within or, … uncommon EGFR mutations (incidence ≤ 5%
each). Evidence on the efficacy of EGFR TKIs in NSCLC patients harboring uncommon EGFR …

… In conclusion, uncommon EGFR mutations may be associated with a poor outcome and the
… in cases of double uncommon mutations and such patients should be treated accordingly. …

… “uncommon” mutations. We conducted a systematic literature review to identify evidence
on uncommon EGFR mutations … /metastatic NSCLC and uncommon EGFR mutations (excluding …

… against major uncommon EGFR mutations including compound mutations, but … uncommon
EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations …

… uncommon EGFR mutations with afatinib. In a pooled analysis assessing the activity of afatinib
in 315 EGFR TKI-naïve patients with uncommon EGFR mutations … and S768I mutations (…

… ) mutations have stepped into the era of targeted therapy. … mutation and their outcome to
subsequent osimertinib in patients of advanced NSCLC harboring uncommon EGFR mutations. …

… The role of the remaining uncommon EGFR mutations remains … uncommon EGFR mutations
other than 20ins and T790M. The mutation patterns, use of different generations of EGFR-…

… have been reported to occur in 10% of patients with NSCLC with EGFR mutations, and
the incidence of uncommon mutations in the cohort included in the present study was 12.24%. …

… these uncommon mutations. Aside from exon 20 insertions, the most prevalent uncommon
EGFR mutations … , which have been collectively referred to as the major uncommon mutations. …

… a database of 693 patients with NSCLC and uncommon EGFR mutations treated with
afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. …